by Andrew Maynard | Dec 1, 2008 | Nanotechnology, Oversight
Navigating the minefield of airborne nanoparticle exposure Nanotechnology—like other emerging technologies—presents a dilemma: If you’re making new substances with uncertain health risks, how low is low enough when it comes to managing exposure? The issue is...
by Andrew Maynard | Nov 15, 2008 | Nanotechnology, Policy
As world leaders congregate in Washington DC this weekend for the G20 summit on the global financial crisis, discussions will be informed in part by what has been described as the “biggest brainstorming on the global agenda that has ever taken place.” I mention this...
by Andrew Maynard | Nov 6, 2008 | Nanotechnology, Oversight
UK Consumer Organization Which? Releases New Report Who needs an emerging technologies blog when you have The Daily Mail? For those of you that missed it, Wednesday’s on-line issue of the British tabloid newspaper highlighted “The beauty creams with nanoparticles...
by Andrew Maynard | Oct 20, 2008 | Nanotechnology, Oversight
Is the RBC Life Sciences® nanotechnology product Slim Shake approved for use by the US Food and Drug Administration (FDA)? According to the BBC Radio 4 science program Frontiers—broadcast on Monday evening—there may be some doubt. But I get ahead of myself. The...
by Andrew Maynard | Oct 5, 2008 | Communication, Engagement, Nanotechnology
The silent rave might seem a rather bizarre social phenomenon; a group of strangers converging in a public place and dancing to their own individual iPod soundtracks. But I have a sneaking suspicion that the emerging technology community has been indulging in the new...
